Term
|
Definition
|
increases cGMP production which relaxes vascular smooth muscle
|
|
|
Term
|
Definition
|
|
Term
|
Definition
|
Competitive inhibition of HMG CoA Reductase
|
|
|
Term
|
Definition
|
Decreased plasma LDL levels, decreased vascular inflammation, improved endothelial cell function
|
|
|
Term
|
Definition
|
hepatotoxicity (serum aminotransferase), skeletal myopathy (serum creatine kinase), teratogen (avoid during pregnancy)
|
|
|
Term
|
Definition
|
metabolized by CYP3A4 or CYP2C9; potential drug interactions (warfarin)
|
|
|
Term
|
Definition
|
CAD (primary and secondary prevention)
|
|
|
Term
|
Definition
|
Cyclooxygenase (COX-1) in platelets
|
|
|
Term
| Aspirin: mechanism of action |
|
Definition
|
irreversible acetylation of enzyme at active site
|
|
|
Term
|
Definition
|
reduced synthesis of thromboxane A2
|
|
|
Term
|
Definition
|
hypersensitivity (aspirin induced asthma), slightly prolonged bleeding time
|
|
|
Term
|
Definition
|
oral administration, renal excretion
|
|
|
Term
|
Definition
|
antithrombotic effect in patients at risk for CAD
|
|
|